A two-drug combination for treating advanced kidney cancer has shown sustained and durable clinical benefit in more than five ...

Inhibrx Biosciences Inc. (NASDAQ:INBX) is one of the most profitable new stocks to buy now. On July 18, it was reported that ...

After 5 years, pembrolizumab plus pemetrexed-platinum was associated with improved overall survival (OS) and progression-free survival compared with placebo plus pemetrexed-platinum in patients with ...

CAMBRIDGE, MA / ACCESS Newswire / July 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on its ...

During a live event, Christine Bestvina, MD, discussed trials of KRAS inhibitors plus immunotherapy in patients with ...

They evaluated pembrolizumab in patients with resectable stage II-IV (M0) cSCC. Patients received 200 mg pembrolizumab every 3 weeks for 4 cycles, followed by 18F-labeled fluorodeoxyglucose-positron ...

Median progression-free survival was 3.7 months, with 44.4% of patients being progression free at 6 months and 32.3% at 12 ...

Results from 2 studies suggest that adding ICIs to treatment can improve outcomes for patients with resectable HNSCC.

New trial results show that pembrolizumab given both before and after surgery for stage 2B-3 melanoma improved event-free survival compared with adjuvant therapy alone.

Pembrolizumab conferred a small but statistically significant survival benefit when added to best supportive care as second-line treatment for patients with advanced hepatocellular carcinoma ...